194 related articles for article (PubMed ID: 34533610)
1. Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
Kaur HB; Vidotto T; Mendes AA; Salles DC; Isaacs WB; Antonarakis ES; Lotan TL
Cancer Immunol Immunother; 2022 Apr; 71(4):943-951. PubMed ID: 34533610
[TBL] [Abstract][Full Text] [Related]
2. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Lotan TL; Kaur HB; Salles DC; Murali S; Schaeffer EM; Lanchbury JS; Isaacs WB; Brown R; Richardson AL; Cussenot O; Cancel-Tassin G; Timms KM; Antonarakis ES
Mod Pathol; 2021 Jun; 34(6):1185-1193. PubMed ID: 33462368
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Sokolova AO; Marshall CH; Lozano R; Gulati R; Ledet EM; De Sarkar N; Grivas P; Higano CS; Montgomery B; Nelson PS; Olmos D; Sokolov V; Schweizer MT; Yezefski TA; Yu EY; Paller CJ; Sartor O; Castro E; Antonarakis ES; Cheng HH
Prostate; 2021 Dec; 81(16):1382-1389. PubMed ID: 34516663
[TBL] [Abstract][Full Text] [Related]
4. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
5. Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.
Hwang J; Shi X; Elliott A; Arnoff TE; McGrath J; Xiu J; Walker P; Bergom HE; Day A; Ahmed S; Tape S; Makovec A; Ali A; Shaker RM; Toye E; Passow R; Lozada JR; Wang J; Lou E; Mouw KW; Carneiro BA; Heath EI; McKay RR; Korn WM; Nabhan C; Ryan CJ; Antonarakis ES
Clin Cancer Res; 2023 Jul; 29(14):2702-2713. PubMed ID: 37126020
[TBL] [Abstract][Full Text] [Related]
6. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
Lozano R; Salles DC; Sandhu S; Aragón IM; Thorne H; López-Campos F; Rubio-Briones J; Gutierrez-Pecharroman AM; Maldonado L; di Domenico T; Sanz A; Prieto JD; García I; Pacheco MI; Garcés T; Llacer C; Romero-Laorden N; Zambrana F; López-Casas PP; Lorente D; Mateo J; Pritchard CC; Antonarakis ES; Olmos D; Lotan TL; Castro E
Eur J Cancer; 2021 Apr; 147():74-83. PubMed ID: 33626496
[TBL] [Abstract][Full Text] [Related]
7. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
[TBL] [Abstract][Full Text] [Related]
8. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J
Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687
[TBL] [Abstract][Full Text] [Related]
9. The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
Jenzer M; Keß P; Nientiedt C; Endris V; Kippenberger M; Leichsenring J; Stögbauer F; Haimes J; Mishkin S; Kudlow B; Kaczorowski A; Zschäbitz S; Volckmar AL; Sültmann H; Jäger D; Duensing A; Schirmacher P; Hohenfellner M; Grüllich C; Stenzinger A; Duensing S
Cancer Immunol Immunother; 2019 Oct; 68(10):1621-1633. PubMed ID: 31549213
[TBL] [Abstract][Full Text] [Related]
10. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
Kimura H; Mizuno K; Shiota M; Narita S; Terada N; Fujimoto N; Ogura K; Hatano S; Iwasaki Y; Hakozaki N; Ishitoya S; Sumiyoshi T; Goto T; Kobayashi T; Nakagawa H; Kamoto T; Eto M; Habuchi T; Ogawa O; Momozawa Y; Akamatsu S
Br J Cancer; 2022 Nov; 127(9):1680-1690. PubMed ID: 35986085
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
13. Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and
Telli ML; Chu C; Badve SS; Vinayak S; Silver DP; Isakoff SJ; Kaklamani V; Gradishar W; Stearns V; Connolly RM; Ford JM; Gruber JJ; Adams S; Garber J; Tung N; Neff C; Bernhisel R; Timms KM; Richardson AL
Clin Cancer Res; 2020 Jun; 26(11):2704-2710. PubMed ID: 31796517
[TBL] [Abstract][Full Text] [Related]
14. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
15. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.
Sztupinszki Z; Diossy M; Krzystanek M; Borcsok J; Pomerantz MM; Tisza V; Spisak S; Rusz O; Csabai I; Freedman ML; Szallasi Z
Clin Cancer Res; 2020 Jun; 26(11):2673-2680. PubMed ID: 32071115
[TBL] [Abstract][Full Text] [Related]
16. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
17. Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype.
van Wilpe S; Simnica D; Slootbeek P; van Ee T; Pamidimarri Naga S; Gorris MAJ; van der Woude LL; Sultan S; Koornstra RHT; van Oort IM; Gerritsen WR; Kroeze LI; Simons M; van Leenders GJLH; Binder M; de Vries IJM; Mehra N
Oncoimmunology; 2022; 11(1):2094133. PubMed ID: 35800157
[TBL] [Abstract][Full Text] [Related]
18. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
19. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
[TBL] [Abstract][Full Text] [Related]
20. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
